Peptides DB
Research-centric peptide and protocol reference hub

AHK-Cu (Copper Tripeptide-3) record · updated 4h ago

Skin & aestheticsHealing & recoveryGrade C · preclinicalResearch use only
All 1 studiesJump to the evidenceCompare
What is AHK-Cu (Copper Tripeptide-3) used for?

AHK-Cu (Copper Tripeptide-3) is a synthetic alanine-histidine-lysine peptide bound to copper, studied topically for stimulating dermal papilla cells and supporting hair follicle health.

How it works: Copper-binding tripeptide (GHK-Cu); tissue-remodeling / regenerative signaling

Primarily researched for · Skin & aestheticsRoute · Topical / subcutaneous

Development stage

where AHK-Cu (Copper Tripeptide-3) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 34 registered trials. It describes the research record, not a recommendation.

Identity
NameAHK-Cu (Copper Tripeptide-3)
Chain length
Molecular weight451.4 Da
FormulaC15H24ClCuN6O4-
Structure typeSmall molecule
ClassSkin
Research levelWell Studied
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 168431292. No verified residue count for this compound.

Pharmacology
MechanismCopper-binding tripeptide (GHK-Cu); tissue-remodeling / regenerative signaling
RouteTopical / subcutaneous
Half-life
Time to peak
Duration
Extraction confidence0.50
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies1
Human / animal / cellular0 / 0 / 1
Highest trial phasePreclinical
Years covered2007
Latest study2mo ago
Publication history
20072007
Research funding
1,371 NIH projects · $24.3M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work
Community reports
Positive Neutral Negative
Records

Study register

1 rowOpen in the library →
StudyTypeYearSummary depth
The effect of tripeptide-copper complex on human hair growth in vitro.
FindingNot reported in abstract.
In vitro2007Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching AHK-Cu (Copper Tripeptide-3) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much AHK-Cu (Copper Tripeptide-3) is discussed should be drawn from it.